ArticleInternational journal of proteomics2015
A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma.
Article in International journal of proteomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Interleukin-1α (IL-1α) in pancreatic ductal adenocarcinoma: implications for immunotherapy and molecular biomarkers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Challenges of early detection of pancreatic cancer.The Journal of clinical investigation · 2025Review
- Review
- A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma.Journal of gastroenterology and hepatology · 2019Review
- Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Article
- The changing face of cancer diagnosis: From computational image analysis to systems biology.European radiology · 2018Article
- Article
- Implementing liquid biopsies into clinical decision making for cancer immunotherapy.Oncotarget · 2017Review
- Protein Array-based Approaches for Biomarker Discovery in Cancer.Genomics, proteomics & bioinformatics · 2017Review
- Early diagnosis of pancreatic cancer: Current trends and concerns.Annals of gastroenterological surgery · 2017Review
- Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer.Nature reviews. Cancer · 2017Review
- Plasma protein profiling in a stage defined pancreatic cancer cohort - Implications for early diagnosis.Molecular oncology · 2016Article
- Diagnostic value of selected markers and apoptotic pathways for pancreatic cancer.Central-European journal of immunology · 2016Review
- Biomarkers in pancreatic adenocarcinoma: current perspectives.OncoTargets and therapy · 2016Review
- Technical Advances of the Recombinant Antibody Microarray Technology Platform for Clinical Immunoproteomics.PloS one · 2016Article
- Article
- Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers.PancreasArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with rapid tumor progression and poor prognosis. This study was motivated by the lack of sensitive and specific PDAC biomarkers and aimed to identify a diagnostic, serum protein signature for PDAC. Methods. To mimic a real life test situation, a multicenter trial comprising a serum sample cohort, including 338 patients with either PDAC or other pancreatic diseases (OPD) and controls with nonpancreatic conditions (NPC), was analyzed on 293-plex recombinant antibody microarrays targeting immunoregulatory and cancer-associated antigens. Results. Serum samples collected from different hospitals were analyzed and showed that (i) sampling from five different hospitals could not be identified as a preanalytical variable and (ii) a multiplexed biomarker signature could be identified, utilizing up to 10 serum markers that could discriminate PDAC from controls, with sensitivities and specificities in the 91-100% range. The first protein profiles associated with the location of the primary tumor in the pancreas could also be identified. Conclusions. The results demonstrate that robust enough serum signatures could be identified in a multicenter trial, potentially contributing to the development of a multiplexed biomarker immunoassay for improved PDAC diagnosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.